Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Specific aspects of erectile dysfunction in endocrinology

International Journal of Impotence Research volume 16, pages S10–S12 (2004)Cite this article

Abstract

Prominent diseases of the endocrine system, such as diabetes mellitus, hypogonadism, and hyperprolactinemia, may cause erectile dysfunction (ED). ED affects about 50% of male diabetic patients possibly due to the vascular and neuropathic complications. Metabolic control and selective phosphodiesterase type 5 inhibitors are therapies of choice for controlling ED. By correcting hypogonadism, testosterone levels are restored. This, and the use of dopaminergic drugs, which normalize prolactin levels in male hyperprolactinemia, may be effective in reversing ED in these endocrine disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Lue TF . Erectile dysfunction. N Engl J Med 2000; 342: 1802–1813.

    Article  CAS  PubMed  Google Scholar 

  2. Koya D, King GL . Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859–866.

    Article  CAS  PubMed  Google Scholar 

  3. Koppiker N, Boolell M, Price D . Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. Endocr Pract 2003; 9: 52–63.

    Article  PubMed  Google Scholar 

  4. Seftel AD et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50: 1016–1026.

    Article  CAS  PubMed  Google Scholar 

  5. Cameron NE, Eaton SE, Cotter MA, Tesfaye S . Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973–1988.

    Article  CAS  PubMed  Google Scholar 

  6. Burns-Cox N, Gingell C . The andropause: fact or fiction? Postgrad Med J 1997; 73: 553–556.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Harman SM et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731.

    Article  CAS  PubMed  Google Scholar 

  8. Bhasin S, Buckwalter JG . Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001; 22: 718–731.

    CAS  PubMed  Google Scholar 

  9. Basaria S, Dobs AS . Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001; 110: 563–572.

    Article  CAS  PubMed  Google Scholar 

  10. Tsujimura A et al. The clinical studies of sildenafil for the ageing male. Int J Androl 2002; 25: 28–33.

    Article  CAS  PubMed  Google Scholar 

  11. Buvat J . Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 2003; 15: 373–377.

    Article  CAS  PubMed  Google Scholar 

  12. Carani C, Granata AR, Fustini MF, Marrama P . Prolactin and testosterone: their role in male sexual function. Int J Androl 1996; 19: 48–54.

    Article  CAS  PubMed  Google Scholar 

  13. De Rosa M et al. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 2003; 20: 75–82.

    Article  CAS  PubMed  Google Scholar 

  14. Wortsman J, Rosner W, Dufau ML . Abnormal testicular function in men with primary hypothyroidism. Am J Med 1987; 82: 207–212.

    Article  CAS  PubMed  Google Scholar 

  15. Naya Y et al. Significant decrease of the International Index of Erectile Function in male renal failure patients treated with hemodialysis. Int J Impot Res 2002; 14: 172–177.

    Article  CAS  PubMed  Google Scholar 

  16. Rendell MS et al. Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426.

    Article  CAS  PubMed  Google Scholar 

  17. Boulton AJ, Selam JL, Sweeney M, Ziegler D . Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001; 44: 1296–1301.

    Article  CAS  PubMed  Google Scholar 

  18. Stuckey BG et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26: 279–284.

    Article  CAS  PubMed  Google Scholar 

  19. Tran D, Howes L . Cardiovascular safety of sildenafil. Drug Saf 2003; 26: 453–460.

    Article  CAS  PubMed  Google Scholar 

  20. Eardley I, Cartledge J . Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56: 300–304.

    CAS  PubMed  Google Scholar 

  21. Hellstrom WJ et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763–771.

    CAS  PubMed  Google Scholar 

  22. Saenz De Tejada I, Anglin G, Knight JR, Emmick JT . Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159–2164.

    Article  PubMed  Google Scholar 

  23. Goldstein I, Young J, Fischer J . Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes 2001; 50: 114.

    Google Scholar 

  24. Montorsi F . Podium Session 2PS-2 Pharmacotherapy. Monday, November 17, 2003, 09:00-10:30D. Hatzichristou, Greece; F. Montorsi, Italy. Int J Impot Res 2003; 15: S3–S4.

    Google Scholar 

  25. Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641–646.

    Article  CAS  PubMed  Google Scholar 

  26. Heaton JP et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13: 317–321.

    Article  CAS  PubMed  Google Scholar 

  27. Snyder PJ et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670–2677.

    CAS  PubMed  Google Scholar 

  28. Wang C et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85: 2839–2853.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Endocrinología, Hospital Clínico Universitario, Paseo de San Vicente, Salamanca, Spain

    J M Miralles-García & L C García-Díez

Authors
  1. J M Miralles-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L C García-Díez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L C García-Díez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miralles-García, J., García-Díez, L. Specific aspects of erectile dysfunction in endocrinology. Int J Impot Res 16 (Suppl 2), S10–S12 (2004). https://doi.org/10.1038/sj.ijir.3901237

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901237

Keywords

This article is cited by

Search

Advanced search

Quick links